Skip to main content

Maetzold Derek J's Form 4 filing

Castle Biosciences IncCSTL · filed Oct 21, 2026

Accession no.
0001628280-26-066724
Filed
Oct 21, 2026, 4:18 PM ET
Trade date
Oct 19, 2026
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 3 non-derivative transactions. Open-market sales total $462.6K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Maetzold Derek JCIK 0001239501Director, Officer (Pres. & Chief Exec. Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Oct 19, 2026Common StockSSaleDisposed−8,580$31.91F2−$273,787.812,484Direct
Oct 19, 2026Common StockSSaleDisposed−3,198$31.91F2−$102,048.184,840Indirect
Oct 19, 2026Common StockSSaleDisposed−2,718$31.91F2−$86,731.384,114Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

This transaction was executed in multiple trades at prices ranging from $31.67 to $32.53, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 3 transactions in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)